Fibronectin is a critical component of the extracellular matrix and alterations to its structure will influence cellular behavior. Matrix fibronectin is subjected to both mechanical and biochemical regulation. The Type III domains of fibronectin can be unfolded in response to increased cellular contractility, included or excluded from the molecule by alternative splicing mechanisms, or released from the matrix by proteolysis. Using inflammatory Cytokine microarrays we found that the alternatively spliced fibronectin Type III domain, FnEDA, and the partially unfolded III-1 domain, FnIII-1c, induced the expression of a multitude of pro-inflammatory cytokines in human dermal fibroblasts, most notably CXCL1-3, IL-8 and TNF-α. FnIII-1c, a peptide representing an unfolded intermediate structure of the first Type III domain has been shown to initiate the toll-like receptor-4 (TLR4)-NFκB-dependent release of cytokines from human dermal fibroblasts (You, et al., J. Biol. Chem., 2010). Here we demonstrate that FnIII-1c and the alternatively spliced FnEDA domain induce a TLR4 dependent activation of p38 MAP kinase and its downstream effector, MAPKAP Kinase-2 (MK-2), to regulate cytokine expression in fibroblasts. RT-qPCR analysis indicated that the p38-MK-2 pathway regulates IL-8 mRNA stability. Interestingly, addition of FnIII-1c and FnEDA synergistically enhanced TLR4-dependent IL-8 release. These data indicate that Fn contains two Type III domains which can activate TLR signaling to induce an inflammatory response in fibroblasts. Furthermore, our data identifies the NF-κB and p38/MK2 signaling pathways as transducers of signals initiated in response to structural changes in fibronectin.

Abstract

Fibronectin is a critical component of the extracellular matrix and alterations to its structure will influence cellular behavior. Matrix fibronectin is subjected to both mechanical and biochemical regulation. The Type III domains of fibronectin can be unfolded in response to increased cellular contractility, included or excluded from the molecule by alternative splicing mechanisms, or released from the matrix by proteolysis. Using inflammatory Cytokine microarrays we found that the alternatively spliced fibronectin Type III domain, FnEDA, and the partially unfolded III-1 domain, FnIII-1c, induced the expression of a multitude of pro-inflammatory cytokines in human dermal fibroblasts, most notably CXCL1-3, IL-8 and TNF-α. FnIII-1c, a peptide representing an unfolded intermediate structure of the first Type III domain has been shown to initiate the toll-like receptor-4 (TLR4)-NFκB-dependent release of cytokines from human dermal fibroblasts (You, et al., J. Biol. Chem., 2010). Here we demonstrate that FnIII-1c and the alternatively spliced FnEDA domain induce a TLR4 dependent activation of p38 MAP kinase and its downstream effector, MAPKAP Kinase-2 (MK-2), to regulate cytokine expression in fibroblasts. RT-qPCR analysis indicated that the p38-MK-2 pathway regulates IL-8 mRNA stability. Interestingly, addition of FnIII-1c and FnEDA synergistically enhanced TLR4-dependent IL-8 release. These data indicate that Fn contains two Type III domains which can activate TLR signaling to induce an inflammatory response in fibroblasts. Furthermore, our data identifies the NF-κB and p38/MK2 signaling pathways as transducers of signals initiated in response to structural changes in fibronectin.

Introduction

The extracellular matrix (ECM) plays an essential role in tissue organization and function. The interaction of cells with the ECM depends primarily on integrin receptors which convey both structural and chemical information into the cell, while reciprocally remodeling the matrix through their regulation of ECM assembly and turnover. How the cell integrates the mechanical and biochemical information present in the ECM to impact cellular function is not well understood. The fibronectin matrix is a complex network of polymerized fibers which undergoes extensive remodeling during the processes of development and tissue repair and during the progression of most diseases (reviewed in [1]). Fibronectin is a plasma protein synthesized by the liver which undergoes a cell-dependent polymerization into a fibrillar extracellular matrix in most tissues. Both plasma-derived and local synthesis by resident stromal cells contribute to the fibronectin which makes up the tissue matrix. The secondary structure of the fibronectin molecule is organized into individually folded domains, termed Types I, II and III, which represent regions of amino acid homology. The Type I and II domains are stabilized by the presence of intra-domain disulfide bonds, while the Type III domains are structurally more labile and subject to mechanical unfolding [2]. There are 15–17 Type III domains in fibronectin and the biological role of many of these domains is not well understood.

Both normal and pathological remodeling of the fibronectin matrix occurs at the biochemical and mechanical level. Typically stromal cells such as fibroblasts are the major orchestrators of fibronectin remodeling. At the biochemical level, fibronectin synthesized by fibroblasts undergoes alternative splicing resulting in the increased expression of two Type III domains termed EDA [3]. These fibronectin isoforms are seen only when tissues are being actively remodeled, such as during periods of tissue repair and in association with fibrosis and inflammation. The fibronectin matrix is sensitive to a variety of proteases which release bioactive fragments from the matrix thereby regulating cell adhesion [4], apoptosis [5], and the release of inflammatory mediators and proteases [6]. In response to mechanical forces, the Type III domains of fibronectin can unfold to either reveal or inhibit biologically active sites within the matrix [7]. Mechanically-regulated sites within the matrix have been implicated in fibronectin polymerization [8–10], motogenic activity [11], cell adhesion [12–15], growth factor binding [16], and bacterial colonization [17].

Extracellular matrix molecules, including fibronectin, have been identified as activators of toll-like receptors (TLRs). TLRs are a
family of transmembrane receptors which function as regulators of the innate immune system and mediate the release of inflammatory cytokines in response to pathogens and damaged tissue [10]. TLRs, initially identified on myeloid cells as pattern recognition receptors which recognized bacterial pathogens or PAMPs (Pathogen-associated molecular patterns), have now been found on most tissue cells including skin fibroblasts [19]. TLRs can also become activated in response to intrinsic molecules in the absence of pathogens. Intracellular molecules released from damaged tissue as well as fragments of extracellular matrix molecules have been termed DAMPs (Damage-associated molecular patterns). These molecules can also elicit an immune response following tissue injury or in response to the changes in tissue composition and organization which accompany a variety of pathologies. Two domains in fibronectin have been reported to activate TLR signaling. The extra Type III domain, FnEDA, stimulates TLR4 dependent cytokine release from mast cells and T cells [20,21]. We have previously shown that a partially unfolded intermediate structure of the first Type III (III-1) domain of fibronectin (FnIII-1c) activates TLR4 and TLR2 mediated cytokine release from skin and lung fibroblasts, respectively [22,23]. This intermediate structure of the unfolded III-1 domain has been predicted to occur in response to cellular generated contractile force and by metalloprotease cleavage. The NMR structure of the III-1 domain revealed a \( \beta \) sandwich containing 7 strands organized into two \( \beta \) sheets (strands G, F, C, D and A, B, E). Simulations of III-1 unfolding by steered molecular dynamics identified a prominent unfolding intermediate in which the A and B strands are separated from the folded core.\(^{[24]}\)\(^{[25]}\) FnIII-1c, on the other hand, demonstrates a higher stability characterized by the Ruoslahti laboratory [25]. The FnIII-1c peptide may also be generated by MMP2 cleavage which gives rise to a peptide with the same N-terminus and similar molecular mass as seen in FnIII-1c [26].

In dermal fibroblasts, FnIII-1c induced the expression of IL-8 and TNF-\( \alpha \) which was dependent on NF-kB and accompanied by the activation of p38 MAP kinase [23,27,28]. The purpose of the present study was to define the relationship of p38 activation to the TLR4-dependent induction of IL-8 by FnIII-1c and to determine whether the EDA domain of fibronectin could also induce cytokine expression in dermal fibroblasts. We show that the NFkB dependent induction of IL-8 in dermal fibroblasts by FnIII-1c is modulated by a p38/MK2 signaling axis which controls IL-8 message stability. We further show that FnEDA and FnIII-1c each activate the same signaling pathways in dermal fibroblasts to induce a similar signature of inflammatory genes. In addition, the effects of FnEDA and FnIII-1c on IL-8 expression are synergistic suggesting that the simultaneous changes in cell contractility, alternative splicing and pericellular proteolysis can lead to an enhanced inflammatory response by resident fibroblasts within a tissue and implicate the topography of the fibronectin matrix as having an important role in the regulation of the innate immune system during periods of tissue remodeling.

Materials and Methods

Reagents and Antibodies

Reagents were purchased from Sigma Chemical Co. (St. Louis, MO) unless otherwise indicated. MK-2 Inhibitor III, BAY 11-7082 and TNF-\( \alpha \) were purchased from EMD Millipore (Billerica, MA). PS-1145 (NF-kB inhibitor) was purchased from Sigma. Blocking antibodies to human TLR4 were purchased from R&D Systems (Minneapolis, MN). Rabbit polyclonal antibodies to phosho-p38 MAP Kinase (Thr180/Tyr182), total p38 MAPK, phosho-HSP27 (Ser62), total MAPKAPK-2 as well as the rabbit mononclonal antibody to phosho-MAPKAPK-2 (Thr384) were purchased from Cell Signaling Technology (Danvers, MA). Antibodies to focal adhesion kinase (FAK) and Lamin A/C (H-110) were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Actinomycin D and SB203580 (p38 Inhibitor) were obtained from Enzo Life Sciences (Farmingham, NY).

Preparation of Recombinant Fibronectin Modules

His-tagged recombinant fibronectin modules, FnIII-1c, FnIII-13 and FnIII-10n were prepared as previously described [27]. EDA cDNA, a gift from Dr. Livingston Van de Water (Albany Medical College, Albany, NY) [14], was inserted into bacterial expression vector pQE-30 in-frame with an N-terminal 6x His Tag (Qiagen, Inc., Valencia, CA). cDNA was then transformed into competent M15 bacteria. EDA was expressed and purified by affinity chromatography using metal-chelating nitriofluorocrylic acid-agarose (Ni-NTA) (Qiagen). EDA recombinant proteins were further purified by passage through a Sephadex G-25 column (GE Healthcare Life Sciences, Pittsburgh, PA), followed by anion-exchange chromatography using a DEAE Sepharose column (GE Healthcare). The purity was assessed by appearance of a single band on SDS-PAGE. All recombinant proteins were assayed for the presence of contaminating endotoxin (<0.25 units/ml of protein) using the limulus amebocyte lysate assay, QCL-1000 (Lonza, Allendale, NJ).

Cell Treatment and Lysis

Human dermal fibroblasts in Dulbecco’s Modified Eagle medium (DMEM, Life Technologies, Grand Island, NY) containing 10% FBS (HyClone Laboratories, Logan, UT) were grown to confluence and then maintained at 37°C in an atmosphere of 8% CO\(_2\). THP-1 cells were purchased from ATCC and maintained in Roswell Park Memorial Institute Media (RPMI-1640) containing 10% FBS, 0.05 mM 2-mercaptoethanol at 37°C in an atmosphere of 5% CO\(_2\). Prior to use in experiments, fibroblast monolayers and THP-1 cells were serum-starved in DMEM or RPMI with 0.1% BSA, respectively for 24 h. When pharmacological inhibitors were used, cells were pre-treated with inhibitor for 1 h prior to treatment with matrix molecules. Specific treatment times and amounts are provided in the Figure legends. For analysis of whole cell lysates, cells were placed on ice post-treatment, washed once in PBS and lysed by 1X SDS-PAGE sample buffer (62.5 mM Tris, pH = 6.8, 2% SDS, 10% Glycerol, and 5% \( \beta \)-mercaptoethanol) supplemented with Complete Protease Inhibitor (Roche Applied Science, Indianapolis, IN). Protein concentrations were assayed with a Bicinchoninic acid protein reagent kit (Thermo Scientific, Rockford, IL) using BSA as a standard monocyte.

Nuclear Protein Extraction

For analysis of nuclear extracts cells were lysed in 10 mM HEPES, pH 7.9, 5 mM KCl, 1.5 mM MgCl\(_2\), 1 mM NaF, 1 mM Na\(_3\)VO\(_4\), and 0.1% Nonidet P-40. Cell lysates were passed through a 24-gauge needle 3 times and centrifuged at 4°C, 3000 x g for 5 min. The nuclear pellet was washed with lysis buffer (62.5 mM Tris, pH = 6.8, 2% SDS, 10% Glycerol, and 5% \( \beta \)-mercaptoethanol) supplemented with Complete Protease Inhibitor (Roche Applied Science, Indianapolis, IN). Protein concentrations were assayed with a Bicinchoninic acid protein reagent kit (Thermo Scientific, Rockfort, IL) using BSA as a standard monocyte.

Immunoblot Analysis

Samples were subjected to gel electrophoresis on SDS-polyacrylamide gels under reducing conditions and were...
transferred onto nitrocellulose membranes (GE Healthcare). For further detection of loading control, membranes were blocked in TBST (Tris-HCL, pH = 7.4, 150 mM NaCl and 0.1% Tween 20) containing 5% w/v BSA and incubated with primary antibodies overnight at 4°C. Secondary antibodies conjugated with horse-radish peroxidase were used and detected by enhanced chemiluminescence reagent (GE Healthcare). Membranes were stripped in 62.5 mM Tris-HCl (pH = 6.8), 2% SDS, and 1% b-mercaptoethanol for 20 min at 60°C to remove previously bound antibodies.

Analysis of IL-8 mRNA Stability

Cells were stimulated with 20 μM FnIII-1c for 2 h. 10 μg/ml actinomycin D (Enzo Life Sciences) was added to stop further transcription in the presence or absence of 20 μM MK-2 Inhibitor III. Total RNA was extracted with RNeasy extraction kit (Qiagen) at 0, 30 and 60 min after treatment with actinomycin D. The integrity and purity of the RNA was assessed by denaturing agarose gel electrophoresis (clean and sharp 28S, 18S and 5S bands), as well as spectrophotometry via Nanodrop. 1.5 μg of RNA from each sample was reverse-transcribed using the RT² First Strand Kit (Qiagen) according to the manufacturer’s instructions. IL-8 and b-actin RT² qPCR Primer Assays (Qiagen) were utilized for cDNA amplification. Quantitative PCR was performed using RT² SYBR Green Mastermix (Qiagen) in a MyiQ Cycler System (Bio-Rad Laboratories). The 2-ΔΔCt method was utilized to measure the relative expression levels of IL-8 and b-actin. The results take into account the values for six separate experiments.

Gene Profiling

Human dermal fibroblasts were grown overnight in complete medium and serum-starved for 24 h prior to treatment with fibronectin modules as previously described [23]. The total RNA was isolated from fibroblasts using RNeasy extraction kit (Qiagen). An RT² First Strand kit (Qiagen) was used to convert 1.5 μg of RNA into cDNA. The cDNA was applied to the Human Inflammatory Response & Autoimmunity PCR Microarray (Qiagen). A MyiQ cycler system (Bio-Rad Laboratories) was
Gene expression profiling was analyzed using an Excel-based PCR array data analysis template provided by the manufacturer. Gene profiling for each sample was done in triplicate. The expression profile shown is the result of one representative experiment.

Human IL-8 Enzyme-Linked Immunosorbent Assay

Human dermal fibroblasts were cultured in 48-well culture plates until 90% confluent. Cells were serum-starved 24 h prior to treatment with fibronectin modules. When pharmacological inhibitors or blocking antibodies were used, cells were pre-treated for 1 h. Following exposure to fibronectin modules 0, 4, 24 or 48 h, cell conditioned medium was collected and analyzed for IL-8 protein expression using a commercially available human ELISA kit (BD Biosciences, San Diego, CA), as directed by the manufacturer.

Results

FnIII-1c regulates IL-8 expression in dermal fibroblasts through TLR4 dependent p38 MAPK/MK-2 signaling

Our previous studies have indicated that a fibronectin peptide representing a mechanically unfolded stable intermediate structure of the first Type III domain (FnIII-1c) induces the expression of inflammatory cytokines in human dermal fibroblasts. IL-8 was a major cytokine induced in these cells in response to FnIII-1c and its expression was dependent on the TLR4 dependent activation of NF-κB [23]. Additionally, we have shown that FnIII-1c also activates p38 MAP kinase in fibroblasts [27,29]. Therefore, experiments were done to determine the role of the p38 MAP kinase signaling in the induction of cytokine expression in dermal fibroblasts by FnIII-1c. The addition of FnIII-1c to human dermal fibroblasts resulted in an increase in phosphorylation of p38 MAP kinase. Activation of p38 MAP kinase by FnIII-1c was dose-dependent and could be detected at the 1–5 μM dose range (Fig. 1A). MAPKAP kinase 2 (MK-2) is a downstream effector of p38 which has been shown to regulate the expression of cytokines in several models of inflammation [30]. We, therefore, evaluated whether MK2 was being activated in human dermal fibroblasts in response to the addition of FnIII-1c. As shown in Fig. 1B, phosphorylation of MK2 was seen in response to FnIII-1c. The effects on MK2 phosphorylation were dose-dependent and occurred over the same concentration range as that seen for FnIII-1c dependent p38 activation (compare with Fig. 1A). Control experiments (Fig. 1C and 1D) indicated that activation of p38 and MK-2 was specific to FnIII-1c as treatment of fibroblasts with other Fn Type III domains (FnIII-10n, FnIII-13) did not result in the phosphorylation of either p38 MAPK or MK-2. These particular Fn domains were selected as controls because they shared characteristics of the FnIII-1c domain, i.e., heparin binding activity (FnIII-13), or a stable intermediate structure obtained by mechanical unfolding (FnIII-10n) [31,32].
To determine whether p38/MK-2 activation by FnIII-1c was dependent on TLR4, blocking antibodies were used to prevent TLR4 signaling. Western blot analysis of FnIII-1c treated fibroblasts showed that phosphorylation of both p38 and MK-2 was completely inhibited when cells were preincubated with blocking antibody to TLR4 (Fig. 1E).

To determine whether the p38/MK2 pathway was involved in the regulation of IL-8 expression in response to FnIII-1c, cells were pre-treated with increasing concentrations of the p38 MAPK inhibitor, SB203580. Treatment with the p38 inhibitor partially attenuated IL-8 expression in response to FnIII-1c (Fig. 2A). Western blot analysis showed that although 0.5 μM SB203580 was sufficient to completely inhibit FnIII-1c induced phosphorylation of MK-2 (Fig. 2B), its inhibitory effect on IL-8 expression was only partial. A similar response was seen with the MK-2 inhibitor which partially blocked IL-8 expression by FnIII-1c (Fig. 2C), even under conditions where MK-2 was completely inhibited from activating its downstream effector, HSP27 (Fig. 2D). Consistent with our previous findings [23], the inhibitors of NFκB activation, PS-1145 and Bay11-7082 completely prevented the secretion of IL-8 in response to FnIII-1c [23]. Combining inhibitors at suboptimal amounts did not increase the level of inhibition beyond that seen with each inhibitor alone (data not shown). These findings suggest that MK-2 and p38 are part of a signaling axis which functions to modulate the NFκB dependent expression of IL-8.

To better understand the relationship between the p38/MK2 and the NF-kB pathways on the FnIII-1c mediated induction of IL-8, experiments were done to determine whether p38 or MK2 regulated the activation of NF-kB. Activation of the NF-kB transcription complex occurs in the cytoplasm and can be characterized by the translocation of the p65/rel A subunit to the nucleus. To determine whether p38 and/or MK-2 play a role in the nuclear translocation of NF-kB by FnIII-1c, cells were treated with FnIII-1c in the presence of the inhibitors to p38 or MK-2 and nuclear extracts were analyzed by Western blot for the presence of p65/rel A. As shown in Figs. 3A and B, FnIII-1c treatment resulted in an increase in nuclear p65/rel A which was unaffected by either the p38 or MK-2 inhibitor indicating that the inhibitory effects of these molecules on IL-8 production did not result from an inhibition of NF-kB activation. Similarly, two inhibitors of NF-kB signaling, PS-1145 and Bay11-8072, were ineffective in blocking FnIII-1c induced activation of p38 (Fig. 3C). These data indicate that the p38 MAPK and NF-kB signaling pathways are activated in parallel by TLR4 in response to FnIII-1c and that they likely function independently to regulate IL-8 expression.

**Figure 3. FnIII-1c activates NF-kB in parallel with the p38 MAPK signaling pathway.** Monolayers of human fibroblasts were serum-starved overnight and treated with the indicated concentration of p38 inhibitor (SB203580), MK-2 inhibitor (MK-2 inhibitor III), or NFκB inhibitors (PS-1145, Bay11-7082) for 1 h. Cells were then stimulated with 20 μM FnIII-1c for 1 h. Cells were lysed and the nuclear fraction isolated and analyzed by Western blot for the presence of NF-kB protein p65/rel A (A). Blots were quantified by densitometry and normalized to total lamin A/C. Values are mean ± S.D. of 3 separate experiments (B). Cytoplasmic fractions were analyzed by Western blot for p-p38 (C). Membranes were stripped and reprobed with an antibody to nuclear Lamin A/C or FAK, which served as loading control. Proposed signaling pathway (D).

doi:10.1371/journal.pone.0102974.g003

**Activation of MK-2 by FnIII-1c increases IL-8 mRNA stability**

Enhancing cytokine mRNA stability is a mechanism of increasing the amplitude and strength of an inflammatory response. The p38/MK2 pathway has been implicated in the regulation of IL-8 message stability in HeLa cells [33]; therefore, we evaluated whether activation of MK-2 by FnIII-1c affected IL-8 mRNA stability in dermal fibroblasts. To evaluate this question, cells were incubated with FnIII-1c for 2 h to induce IL-8 expression and then treated with actinomycin-D in the presence or absence of the inhibitor of MK2. IL-8 mRNA levels were
performed in duplicate. The mRNA level was analyzed relative to the blank control and the SD of 12 samples. Data are combined from 6 experiments performed in duplicate.

Figure 4. Activation of MK-2 by FnIII-1c regulates IL-8 mRNA stability. Monolayers of dermal fibroblasts were serum-starved overnight and incubated with 10 μM III-1c for 2 h prior to the addition of 10 μM actinomycin D with or without 20 μM MK-2 inhibitor. After incubation for the indicated times, IL-8 mRNA levels were assessed by RT-PCR. The mRNA level was analyzed relative to the blank control and balanced with the housekeeping gene, β-actin using AΔΔCt (A). The percent (%) change in mRNA expression between 0–30 min and 30–60 min was calculated and analyzed using a two way ANOVA followed by t-test with Bonferroni correction (p<0.05) (B). Error bars indicate mean ± 5D of 12 samples. Data are combined from 6 experiments performed in duplicate.

doi:10.1371/journal.pone.0102974.g004

analyzed by qPCR at 0, 30 and 60 min after the addition of actinomycin D. IL-8 mRNA levels decreased markedly within an hour. At both the 30 and 60 min time points, cells treated with the MK-2 inhibitor exhibited less IL-8 mRNA than did the untreated controls. Analysis of the data at 30 min intervals (Fig. 4B) showed that the initial rate of decay (0–30 min) was twice as fast in cells which were treated with the MK2 inhibitor, suggesting MK-2 activity prolonged the half-life of IL-8 message. MK2 did not appear to influence the message decay rate at later times (30–60 min). These data suggest that the p38/MK-2 pathway stabilizes IL-8 mRNA expression by dampening the initial rates of decay.

FnIII-1c and FnEDA induce a similar inflammatory signature in dermal fibroblasts

Earlier studies have documented a role for the alternatively spliced EDA isoform of fibronectin in the activation of TLR4 signaling and cytokine release in immune cells [20,21]. Expression of the EDA isoform of fibronectin is restricted to tissues undergoing active remodeling, such as during development and wound healing and in association with tissue fibrosis and inflammation. To address whether the EDA domain of fibronectin could also induce the expression of cytokines in dermal fibroblasts, we used the Human Autoimmune and Inflammatory Cytokine microarray to compare the expression profile of inflammatory genes induced in dermal fibroblasts treated individually with these fibronectin domains. Incubation of dermal fibroblasts with FnIII-1c resulted in the increased expression of approximately 20 genes (Fig. 5A). In particular, the expression of 5 genes, chemokine ligand-1, -2 and -3 (CXCL1, CXCL2, CXCL3), Interleukin-8 (IL-8) and tumor necrosis factor-alpha (TNF-α) were increased greater than 1000 fold within 2 hours (Fig. 5B). A similar response was seen using the FnEDA domain (Fig. 5C), where the same 5 genes were selectively increased (Fig. 5D). In contrast, cells incubated with either the FnIII-10n or FnIII-13 showed little change in the expression of any genes (Fig. 5E and F). Tenascin-C is an extracellular matrix protein which is expressed in injured tissues, tumors and fibrotic diseases [reviewed in [34]], where it functions as a DAMP to induce TLR4-dependent cytokine expression in smooth muscle cells [35]. However, Tenascin-C was unable to induce cytokine expression in dermal fibroblasts (Fig. 5G), suggesting that dermal fibroblasts selectively respond to fibronectin-derived DAMPs. As shown in Fig. 6A, addition of either FnIII-1c or FnEDA to dermal fibroblasts resulted in an increase in the expression of IL-8. IL-8 accumulated in the medium for several hours in response to FnIII-1c reaching an apparent steady state by 24 h. FnEDA also induced IL-8 expression but with somewhat slower kinetics, however, both domains resulted in similar concentrations of IL-8 in the conditioned medium by 48 h (18–20 ng/ml). The effects of both FnEDA and FnIII-1c on IL-8 concentration was dose-dependent (Fig. 6B). The difference in the relative amounts of IL-8 induced by each module reflects differences in the rates of accumulation in the medium at the 4-h time point (see Fig. 6A). Neither FnIII-10n nor FnIII-13 induced IL-8 expression.

Bacterial lipopolysaccharide (LPS) is the canonical ligand for TLR4. It is a well-established activator of TLR4-dependent cytokine release in immune cells [reviewed in [36]]. However, when added to dermal fibroblasts, LPS was unable to induce IL-8 expression in dermal fibroblasts (Fig. 6C). As expected, both Tenascin-C and LPS induced IL-8 expression in the monocytic cell line, THP-1 (Fig. 6C and D). These data suggest that the induction of an inflammatory response by TLR4 ligands is cell-type specific.

To determine whether the NF-κB and the p38/MK-2 signaling pathways play a role in IL-8 induction in response to FnEDA, cells were incubated with FnEDA in the presence of various inhibitors of the TLR4 signaling pathway. As shown in Fig. 6E and F, induction of IL-8 in response to either FnIII-1c or FnEDA was completely inhibited by blocking antibody to TLR4 consistent with FnEDA and FnIII-1c both working through TLR4 to induce cytokine expression. The inhibitor of the NF-κB pathway (BAY) completely blocked IL-8 expression indicating that gene expression in response to either FnIII-1c or FnEDA was regulated by NF-κB. The inhibitor of p38 or its down-stream effector, MK-2, only partially blocked the induction of IL-8 by either FnIII-1c or FnEDA. These data suggest that both the FnEDA and FnIII-1c work through NF-κB and p38/MK-2 signaling to induce an inflammatory response in dermal fibroblasts.
FnEDA-enhancement of FnIII-1c induced IL-8 release

Our data demonstrate that FnIII-1c and FnEDA induce the expression of IL-8 through the same molecular mechanism in dermal fibroblasts. Activation of the p38 MAPK and NF-κB signaling pathways, as well as induction of IL-8, was shown to be dependent on TLR4 activity. Enhancement of TLR4 activation as a result of ligand sensitizing molecules has been well documented in a variety of immune cells [37]. Here we evaluated the combined effect of the FnEDA and FnIII-1c domains on IL-8 expression. FnEDA and FnIII-1c were added to cells in amounts well below saturation. As shown in Fig. 7A, when added individually at 2 μM, FnIII-1c and FnEDA respectively induced 100 or 200 ng/ml IL-8 over a 4-h period. However, when both modules were added simultaneously, IL-8 induction was increased to 2.5 ng/ml. This amount is 8 fold greater than the expected additive effect of 0.3 ng/ml. These results suggest a synergistic effect of these two domains on cytokine expression. To examine this synergism more closely, cells were incubated with increasing concentrations of FnIII-1c in the presence of a fixed amount of FnEDA. As shown in Fig. 7B, when cells were incubated with FnEDA at amounts low enough to yield little detectable IL-8, the production of IL-8 in response to FnIII-1c was enhanced at all doses. When analyzed over the complete dose range of FnIII-1c, the addition of a fixed amount of FnEDA shifted the effective dose curve of FnIII-1c to the left consistent with FnEDA sensitizing the cells to FnIII-1c (Fig. 7C). In the absence of FnEDA, induction of IL-8 by FnIII-1c was half-maximal at approximately 9 μM FnIII-1c. In the presence of FnEDA, half-maximal IL-8 induction was seen at 0.9 μM FnIII-1c, suggesting at 10-fold shift in sensitivity of the cells to FnIII-1c. These experiments used μM concentrations of fibronectin peptides in short-term (4 h) incubations to generate relatively large amounts of IL-8 (5-20 ng/ml). High affinity receptors for IL-8 can be activated at nM concentrations of IL-8, peptides were combined at nM concentrations and incubated with cells for 24 h. Figure 7D shows that the FnIII-1c and FnEDA could generate an IL-8 response at doses between 50–100 nM.

Discussion

Previous experiments have demonstrated that alterations to fibronectin structure, both biochemical and mechanical, occur during periods of active ECM remodeling. Emerging data indicate that alterations to fibronectin structure (i.e., inclusion of alternatively spliced EDA domain) can lead to activation of innate immune responses via TLRs [22,23,39]. The present study demonstrates that two Type III domains from fibronectin, one regulated by mechanical force and proteolysis (FnIII-1) and a second regulated by alternative splicing of mRNA (FnEDA), can induce pro-inflammatory cytokine expression through NF-κB-dependent gene transcription and subsequent mRNA stability controlled by the p38-MK-2 signaling axis. Activation of the p38-MK-2 signaling axis and induction of IL-8 gene expression, by both FnIII-1c and FnEDA, was shown to be dependent on TLR4 indicating a link between the fibroblasts responsible for the remodeling of the ECM and the innate immune system.

Both FnIII-1c and FnEDA induced a similar pro-inflammatory gene signature in human dermal fibroblasts. CXCL-1,-2,-3, TNF-alpha and IL-8 were the most highly upregulated cytokines. Typically in a normal tissue microenvironment there are low levels of these pro-inflammatory mediators, as their expression is tightly regulated by a variety of molecular mechanisms. In part, this is due to the fact that the mRNA of pro-inflammatory cytokines is extremely short-lived and rarely becomes translated into protein as a result of the prominence of AU-rich elements in the 3'-untranslated region. However, when damage or pathogenic infection occurs, the cytokine mRNAs become rapidly stabilized, resulting in an innate immune response mounted by stromal components of the tissue [40]. Upon stimulation of the TLR
family, downstream signaling pathways, such as p38 MAP Kinase, are activated to prolong mRNA stability [41,42]. More specifically, the downstream substrate of p38 MAPK, MK-2, can phosphorylate and inactivate AU-binding proteins, thereby stabilizing cytokine mRNA expression by dampening the initial rates of decay [43,44]. These signaling pathways are known to be activated downstream of TLR4 in a variety of immune cells [45,46]. We have now demonstrated that this signaling axis controls cytokine expression in dermal fibroblasts in response to TLR4 activation. Our data also identified FnIII-1c and FnEDA as novel activators of p38/MK-2 signaling, ultimately leading to the enhanced stabilization of IL-8 mRNA.

Pharmacological inhibition of the p38 MAPK pathway has long been studied as a potential therapeutic avenue to promote anti-inflammatory effects in rheumatoid arthritis, cirrhosis, fibrosis and cancer [47]. However, the p38 MAPK inhibitors are ATP competitors that can cross-react with other kinases, resulting in detrimental side-effects [48] and alternative mechanisms to block aberrant signaling of p38 MAPK/MK-2 need to be investigated. Targeting mechanisms regulating fibronectin secondary structure (i.e., mechanical unfolding, proteolysis) or alternative splicing (EDA→fibronectin) may prove to be an effective alternative to dampen inflammation within a fibronectin-rich microenvironment.

A wide range of ECM-derived DAMPs have been identified as activators of TLR4 signaling in a variety of cell types [49]. MD-2, myeloid differentiation factor-2, is the LPS-binding constituent of the TLR4 receptor complex and it is often required for activation of downstream signaling pathways [50,51]. The ligand specificity of TLR4 signaling, however, can be regulated through distinct ancillary proteins or co-receptors, such as CD14, CD44 and CD36, which are responsible for ligand delivery to the TLR4/MD-2 complex [35,52,53]. Whether these distinct receptor complexes function on the same cell to regulate differential

---

**Figure 6. IL-8 expression induced by FnIII domains is NF-κB and TLR4-dependent.** Fibroblasts were serum-starved overnight before treatment with 20 μM FnIII-1c, FnEDA, FnIII-10n, FnIII-13 or PBS in 0.1% BSA-DMEM for the indicated amount of time (A) or for 4 h at the indicated dose (B). Fibroblasts or THP-1 monocytes were incubated with increasing doses of LPS for 4 h (C). Tenascin C (100 μg/ml), LPS (1 μg/ml) or FnEDA (200 μg/ml) were incubated with either dermal fibroblasts or THP-1 monocytes for 4 h (D). Cells were pretreated with the indicated amounts of inhibitor or monoclonal antibody for 1 h prior to the addition of FnIII-1c (E) or FnEDA (F) in 0.1% BSA-DMEM for 4 h. In all experiments, conditioned media was collected and IL-8 protein amounts determined by ELISA. To determine significance, statistical analysis was performed using Student’s t test. *p<0.05. Error bars indicate mean ± S.D. of three separate experiments performed in triplicate.

doi:10.1371/journal.pone.0102974.g006
TLR4 signaling in response to different ligands has not been demonstrated. Furthermore, it is not clear whether co-receptors are responsible for differential gene expression in response to a single ligand. For example, Midwood, et al. [35] demonstrated that Tenascin C induced the TLR4 dependent expression of IL-6 in synovial fibroblasts. In contrast, Tenascin C elicited a more elaborate cytokine profile in macrophages: IL-6, IL-8 and TNF-α. In our studies, LPS and Tenascin-C did not elicit an inflammatory response in dermal fibroblasts, but did induce an IL-8 response in monocytic cells. This suggests that dermal fibroblasts may not express co-receptors required to activate TLR4 signaling by LPS or Tenascin C. The ability of dermal fibroblasts to respond to fibronectin Type III domains indicates that the co-receptors required for TLR4 activation, in response to Tenascin C may be different from those required by FnIII-1c or FnEDA. These data suggest that heterogeneity of TLR-4 containing receptor complexes may regulate the cellular response to individual ligands thereby providing a mechanism by which cells can selectively regulate their response to individual TLR4 activators. The existence of receptor complexes which can differentially regulate the cellular response to DAMPs and PAMPs suggests that it is possible to design therapeutics to target chronic inflammation while maintaining host defense.

The physiological conditions under which the FnIII-1 and FnEDA domains activate inflammatory pathways are not well understood. The fibronectin matrix is a highly dynamic structure that undergoes continuous assembly and turnover in most tissue. Mechanically regulated cryptic sites, proteolysis and changes in alternative splicing of matrix fibronectin are emerging as influential events in the acquisition of disease-associated phenotypes [54]. Proteomic analysis has indicated that both the EDA domain and the III-1c peptide could be released from the matrix by MMP2 [26]. Although the presence of fibronectin fragments has been documented in injured and disease tissue [6,55–57], little is known about their specific sequences and concentrations within the local microenvironment. Force-induced unfolding of the FnIII-1 domain has been shown to expose cryptic activity regulating fibronectin polymerization [9,58,59], cell growth [60,61] and skeletal muscle contraction [60,61]. However, little is known about the contribution of these unfolded Type III domains to the inflammatory response. Interestingly, fibronectin has been linked to mechanically-induced activation of NFκB and IL-8 induction in endothelial cells and amniotic epithelium [62,63], consistent with the concept that force-induced unfolding of Type III domains within fibronectin may contribute to cytokine release under physiological conditions. Recently, UV absorption microscopy has estimated the concentration of fibronectin in a polymerized fibronectin fiber at 177 mg/ml suggesting a local concentration of fibronectin of up to 400 μM [64]. Limited fiber proteolysis would therefore be expected to generate the levels of Fn peptides required for a robust induction of IL-8.
In the adult, matrix fibronectin is constantly replenished by fibronectin from the plasma [63–66]. Plasma fibronectin is synthesized by the liver and does not contain the EDA domain. Resident tissue cells, primarily fibroblasts, polymerize plasma fibronectin into the stromal matrix; however, in response to injury or during wounding processes, resident cells synthesize cellular fibronectin, which is alternatively spliced to include the extra domains, EDA and EDB. The EDA domain is considered a marker for fibrosis [69] and neovascular metastasis [70]. EDA-mediated TLR4 signaling is thought to contribute to adverse inflammation following cardiac infarction [71], cerebral ischemia [72], allergen challenge [73], graft vs. host disease [74], and preterm birth [75]. Our data provide the first evidence that biochemical and/or mechanical alterations in the topography of the fibronectin matrix may work coordinately and synergistically to maximize the tissue response to damage. While both the FnEDA and FvIII-1c domains induce identical cytokine profiles through the same signaling pathways, their effects on cytokine expression are synergistic rather than additive. This synergy suggests unshared but interactive aspects of their individual mechanisms of action. Our data further suggest that alternative splicing of fibronectin to include the EDA domain may act as a priming event to sensitize cells to respond more rapidly to matrix damage following mechanical or proteolytic insult and point to the organization and composition of the fibronectin matrix as a previously unrecognized target for the control of chronic tissue inflammation.

Author Contributions
Conceived and designed the experiments: PJM MZ RK RY. Performed the experiments: RK RY. Analyzed the data: RK RY MZ PJM. Contributed reagents/materials/analysis tools: CH RK RY MZ. Wrote the paper: RK PJM. Provided helpful comments on the manuscript: MZ.

References
1. Bradshaw MJ, Smith ML (2013) Multiscale relationships between fibronectin structure and functional properties. Acta Biomater. Available: http://dx.doi.org/10.1016/j.actbio.2013.08.027.
2. Peleg O, Savin T, Kolmakov GV, Salib IG, Balazs AC, et al. (2012) Fibers with integrated mechanoswitches: minimalistic design principles derived from fibronectin. Biophys J 103: 1909–1919.
3. Muro AF, Lianou G, Baralle FE (1996) Regulation of the fibronectin EDA exon alternative splicing. Cooperative role of the exon enhancer element and the 5′ splicing site. FEBS Lett 373: 137–141.
4. Watanabe K, Takahashi H, Habu Y, Kamiya-Kubushiro N, Kamiya S, et al. (2000) Recognition of the 5′-flanking region by the pre-mRNA splicing factor SF2/ASF is regulated by interactions with cell-specific proteins and the fibronectin 5′ UTR. J Biol Chem 275: 14427–14433.
5. Schepers P, Strange R, Mitterenga T, Wolfe P, Kaeck M (2000) Fibronectin fragments induce MMP activity in mouse mammary epithelial cells: evidence for a role in matrix turnover. J Cell Sci 113: 795–806.
6. Sofat N (2009) Analysing the role of endogenous matrix molecules in the development of osteoarthritis. Int J Exp Pathol 90: 469–477.
7. Smith ML, Gourdon D, Little WC, Kubow KE, Eguiluz RA, et al. (2007) Force-induced unfolding of fibronectin in the extracellular matrix of living cells. PLoS Biol 5 (e268): 2249–2254.
8. Hocking DC, Smith RK, McKeown-Longo PJ (1996) A novel role for the integrin-binding III-10 module in fibronectin matrix assembly. J Cell Biol 133: 411–414.
9. Zhong C, Chrzanowska-Wodnicka M, Brown J, Shab A, Belkin AM, et al. (1998) Rh-mediated contractility exposes a cryptic site in fibronectin and induces fibronectin matrix assembly. J Cell Biol 141: 539–551.
10. Gee EP, Yukoel D, Stultz CM, Ingber DE (2013) SLiSWSV sequence in the 10FNIII domain initiates fibronectin fibrillogenesis. J Biol Chem 288: 21329–21340.
11. Vakonakis I, Staunton D, Ellis IR, Sarkies P, Flanagan A, et al. (2009) The fibronectin 1b isoform is essential for the development of osteoarthritis. EMBO J 28: 2858–2870.
12. Krammer A, Craig D, Thomas WE, Schulten K, Vogel V, et al. (2002) A structural model for force-regulated integrin binding to fibronectin’s RGF-synergy site. Matrix Biol 21: 139–147.
13. Mao Y, Schwarzbauer JE (2005) Stimulatory effects of a three-dimensional microenvironment on cell-mediated fibronectin fibrillogenesis. J Cell Sci 118: 4427–4436.
14. Shinde AV, Bystroff C, Wang C, Vogelezang MG, Vincent PA, et al. (2008) Identification of the peptide sequences within the EIIIA (EDA) segment of fibronectin that mediate integrin α9β1-dependent cellular activities. J Biol Chem 283: 28969–28979.
15. Miura S, Kamiya S, Saito Y, Wada S, Hayashi R, et al. (2007) Antiahesive sites previously unrecognized target for the control of chronic tissue inflammation. J Leukocyte Biol 87: 989–999.
16. Shin WS, Ngoc T, Duong TV, Smith KL, Hertel MA, et al. (2004) Fibronectin 2a is a functional antagonist of fibronectin 1a and inhibits both cell adhesion and cell spreading. J Cell Sci 117: 2847–2855.
17. Chabria M, Hertz S, Smith ML, Vogel V (2010) Stretching fibronectin fibers disrupts binding of bacterial adhesins by physically destroying an epitope. Nature Communications 1: 135.
18. O’Neill LA, Bryant CE, Doyle SL (2009) Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol Rev 61: 177–197.
19. Terhoost D, Kalali BN, Olney M, Ring J, Mempel M (2010) The role of toll-like receptors in host defenses and their relevance to dermatologic diseases. Am J Clin Dermatol 11: 1–10.
Fibronectin Regulates Cytokine Release

39. Okamura Y, Watari M, Jerud ES, Young DW, Ishizaka ST, et al. (2001) The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem 276: 10229–10233.

40. Knapinska AM, Irizarry-Barreto P, Ahsanullah S, Andorsalakis I, Brewer G (2003) Molecular mechanisms regulating mRNA stability: Physiological and pathological significance. Current Genomics 6: 471–486.

41. Akira S (2005) Mammalian Toll-like receptors. Curr Opin Immunol 15: 5–11.

42. Bowie A, O’Neill LAJ (2000) The interleukin-1 receptor/Toll-like receptor superfamily: signal generators for pro-inflammatory interleukins and microbial products. J Leuk Biol 67: 508–514.

43. Frevel MAE, Bahkert T, Silva AM, Hisong JG, Khabar KSA, et al. (2003) p38 Mitogen-activated protein kinase-dependent and -independent signaling of mRNA stability of AU-rich element-containing transcripts. Mol Cell Biol 23: 425–436.

44. Neininger A, Kontoyiannis D, Kotlyarov A, Winzen R, Eckert R, et al. (2002) MK2 targets AU-rich elements and regulates bioavailability of tumor necrosis factor and interleukin-6 independently at different post-transcriptional levels. J Biol Chem 277: 3065–3068.

45. An H, Yu Y, Zhang M, Xu H, Qi R, et al. (2002) Involvement of ERK, p38 and NF-kB signal transduction in regulation of TLR2, TLR4 and TLR9 gene expression induced by lipopolysaccharide in mouse dendritic cells. Immunology 106: 38–45.

46. Bode JG, Ehling C, Hausinger D (2012) The macrophage response towards LPS and its control through the p38MAPK-STAT3 axis. Cell Signal 24: 1185–1194.

47. Kumar P, Amin MA, Harlow LA, Polverini PJ, Koch AE (2003) Src and phosphatidylinositol 3-kinase mediate soluble E-selectin-induced angiogenesis. Blood 101: 3960–3968.

48. Sweeney SE, Firestein GS (2006) Mitogen activated protein kinase inhibitors: where are we now and where are we going? Ann Rheum Dis 65 (Suppl III): iii83–iii88.

49. Miyake K (2006) Roles for accessory molecules in microbial recognition by Toll-like receptors. J Endotoxin Res 12: 195–204.

50. Park BS, Song DH, Kim HM, Choi BS, Lee H, et al. (2009) The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex dependent on toll-like receptor 4, CD44, and MD-2. J Biol Chem 282: 18265–18275.

51. Akira S (2003) Mammalian Toll-like receptors. Curr Opin Immunol 15: 5–11.

52. Stewart CR, Stuart LM, Wilkinson K, van Gils JM, Deng J, et al. (2010) CD36 and 6 heterodimer. Nat Immunol 11: 155–161.

53. Taylor KR, Yamasaki K, Radek KA, DiNardo A, Goodarzi H, et al. (2007) Recognition of hyaluronan released in sterile injury involves a unique receptor complex dependent on toll-like receptor 4, CD44, and MD-2. J Biol Chem 282: 18265–18275.

54. Kelsh RM, McKeown-Longo PJ (2013) Topographical changes in extracellular matrix Activation of TLR4 signaling and solid tumor progression. Trends in Cancer Res 9: 1–13.

55. Scorpion DC, Sontelle J, McKeown-Longo PJ (1994) Fibronectin’s III-1 module contains a conformation-dependent binding site for the amino-terminal region of toll-like receptor 4. J Biol Chem 269: 19183–19187.

56. Hocking DC, Kowalski K (2002) A cryptic fragment from fibronectin’s III1 module localizes to lipid rafts and stimulates cell growth and contractility. J Cell Biol 156: 175–184.

57. Hocking DC, Titin PA, Sumagin R, Savelius HI (2008) Extracellular matrix fibronectin mechanically couples skeletal muscle contraction with local vasodilatation. Circ Res 102: 372–379.

58. Feaver RE, Geissler BD, Wang C, Schwartz MA, Blackman BR (2010) Atheroprotein hemodynamics regulate fibronectin deposition to create positive feedback that sustains endothelial inflammation. Circ Res 106: 1703–1711.

59. Kendall-Wright CE, Hubbard D, Goswin-Brown JH, Bryant-Greenwood GD (2010) Stress and inflammation-induced Pre-B cell colony-enhancing factor (PreB/Fas/Viafin) and interleukin-8 in amniotic epithelial cells. Placenta 31: 665–674.

60. Bradshaw MJ, Cheung MC, Ehrlich DJ, Smith ML (2012) Using molecular mechanics to predict bulk material properties of fibronectin fibers. PLoS Comput Biol 8: e1002145- doi:10.1371/journal.pcbi.1002145. Epub 2012 Dec 27.

61. Dero DC, Saha TM, Lewis EP (1983) Genetics of endogenously labeled plasma fibronectin: Incorporation into tissues. Am J Physiol 245: R564–R575.

62. Moretti FA, Chauhan AK, Laconig A, Porr no F, Barelle FE, et al. (2007) A major fraction of fibronectin present in the extracellular matrix of tissues is plasma-derived. J Biol Chem 282: 20057–20062.

63. Oh E, Pierschbacher M, Raoelalili E (1981) Deposition of plasma fibronectin in tissues. Proc Natl Acad Sci 78: 3218–3221.

64. Thompson C, Blumentock FA, Saha TM, Frustal PJ, Kaplan JE, et al. (1989) Plasma fibronectin synthesis in normal and injured humans as determined by stable isotope incorporation. J Clin Invest 84: 1226–1235.

65. Booth AJ, Wood SC, Cornett AM, Drelli AA, Li G, et al. (2012) Recipient-derived EDA fibronectin promotes cardiac allograft fibrosis. J Pathol 226: 609–619.

66. Feaver RE, Geissler BD, Wang C, Schwartz MA, Blackman BR (2010) Atheroprotein hemodynamics regulate fibronectin deposition to create positive feedback that sustains endothelial inflammation. Circ Res 106: 1703–1711.

67. Volz KS, Miljan E, Khoo A, Cooke JP (2012) Development of pluriopotent stem cells for vascular therapy. Vascul Pharmacol 56: 288–296.

68. Arslan F, Smeets MB, Riem N, van Dijk MR, Castigliego D, Borst HP, et al. (2004) Extra-domain-A fibronectin: a new marker of fibrosis in pathological significance. Current Genomics 6: 471–486.

69. Kendal-Wright CE, Hubbard D, Goswin-Brown JH, Bryant-Greenwood GD (2010) Stress and inflammation-induced Pre-B cell colony-enhancing factor (PreB/Fas/Viafin) and interleukin-8 in amniotic epithelial cells. Placenta 31: 665–674.

70. Arslan F, Smeets MB, Riem N, van Dijk MR, Castigliego D, Borst HP, et al. (2004) Extra-domain-A fibronectin: a new marker of fibrosis in pathological significance. Current Genomics 6: 471–486.

71. Arslan F, Smeets MB, Riem N, van Dijk MR, Castigliego D, Borst HP, et al. (2004) Extra-domain-A fibronectin: a new marker of fibrosis in pathological significance. Current Genomics 6: 471–486.

72. Khan MM, Gandhi C, Chauhan N, Stevens JW, Motto DG, et al. (2012) Development of pluriopotent stem cells for vascular therapy. Vascul Pharmacol 56: 288–296.

73. Arslan F, Smeets MB, Riem N, van Dijk MR, Castigliego D, Borst HP, et al. (2004) Extra-domain-A fibronectin: a new marker of fibrosis in pathological significance. Current Genomics 6: 471–486.

74. van der Straaten HM, Canninga-van Dijk MR, Verdonck LF, Castigliego D, Borst HP, et al. (2004) Extra-domain-A fibronectin: a new marker of fibrosis in pathological significance. Current Genomics 6: 471–486.

75. Mogami H, Kishore AH, Shi H, Keller PW, Akgul Y, et al. (2013) Development of pluriopotent stem cells for vascular therapy. Vascul Pharmacol 56: 288–296.

76. Arslan F, Smeets MB, Riem N, van Dijk MR, Castigliego D, Borst HP, et al. (2004) Extra-domain-A fibronectin: a new marker of fibrosis in pathological significance. Current Genomics 6: 471–486.

77. Kendal-Wright CE, Hubbard D, Goswin-Brown JH, Bryant-Greenwood GD (2010) Stress and inflammation-induced Pre-B cell colony-enhancing factor (PreB/Fas/Viafin) and interleukin-8 in amniotic epithelial cells. Placenta 31: 665–674.

78. Arslan F, Smeets MB, Riem N, van Dijk MR, Castigliego D, Borst HP, et al. (2004) Extra-domain-A fibronectin: a new marker of fibrosis in pathological significance. Current Genomics 6: 471–486.

79. Kendal-Wright CE, Hubbard D, Goswin-Brown JH, Bryant-Greenwood GD (2010) Stress and inflammation-induced Pre-B cell colony-enhancing factor (PreB/Fas/Viafin) and interleukin-8 in amniotic epithelial cells. Placenta 31: 665–674.